Comparing Adherence and Persistence Across 6 Chronic Medication Classes

Yeaw, Jason; Benner, Joshua S.; Walt, John G.; Sian, Sergey; Smith, Daniel B.

doi:10.18553/jmcp.2009.15.9.728

Cited by 494 publications

(426 citation statements)

References 32 publications

(45 reference statements)

Supporting

Mentioning

390

Contrasting

Unclassified

Order By: Relevance

“…When selecting a measure defini proportion of days in a measurement period that patients have their prescribed medication on hand. [26][27][28][29] These measures are highly correlated with other methods of measuring adherence. 30 Concurrent adherence measures build on these individual measures, calculating a PDC that reflects all medications that patients are prescribed for use together.…”

Section: What This Study Addsmentioning

confidence: 98%

“…8,16,[18][19]29,40 First, we counted days supplied over the full study year as the sum of days supplied for each fill for a drug in each oral antidiabetic class, plus any days remaining from previous year fills, truncated at year end. We counted medication switches within the same class (e.g., from a branded to a generic or from one generic to another) as medication use within that class.…”

Section: 34mentioning

confidence: 99%

“…Using the All definition, we considered patients adherent when their PDC was 0.80 or above for each medication; using the Average definition, we considered patients adherent when the mean PDC across all of their oral antidiabetic medications was at least 0.80-the 0.80 threshold is used in many studies to identify patients as adherent or nonadherent. 5,8,10,16,[18][19]26,29 To calculate Any concurrent adherence, we counted days on which any oral antidiabetic was available and considered patients adherent when the PDC calculated was at least 0.80. This Any definition did not require that patients have a specific oral antidiabetic or specific class oral antidiabetic available during our measurement period.…”

Section: 34mentioning

confidence: 99%

See 2 more Smart Citations

The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?

Sacks¹,

Burgess²,

Cabral³

et al. 2015

JMCP

View full text Add to dashboard Cite

BACKGROUND: Accurate estimates of the effects of cost sharing on adherence to medications prescribed for use together, also called concurrent adherence, are important for researchers, payers, and policymakers who want to reduce barriers to adherence for chronic condition patients prescribed multiple medications concurrently. But measure definition consensus is lacking, and the effects of different definitions on estimates of cost-related nonadherence are unevaluated.

show abstract

Section: What This Study Addsmentioning

confidence: 98%

Section: 34mentioning

confidence: 99%

Section: 34mentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?

Sacks¹,

Burgess²,

Cabral³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

“…53 Despite this effi cacy data, adherence to oral bisphosphonates remains poor, with 12-month adherence estimated to be approximately 60%. 54 Although osteonecrosis of the jaw is a well publicised adverse effect associated with the bisphosphonates, it is rare (incidence rate: <1 in 10,000/patient-treatment years), particularly within the context of those receiving oral bisphosphonates for osteoporosis. 55 Good oral hygiene, regular dental checkups and heightened care when undergoing periodontal procedures may help prevent this complication.…”

Section: Bisphosphonatesmentioning

confidence: 99%

Drug therapies in older adults (part 1)

Mukhtar

Jackson

2015

Clinical Medicine

View full text Add to dashboard Cite

Prescribing for older adults represents a signifi cant challenge as the UK population ages. Physiological decline and the rising prevalence of frailty increase the likelihood of altered pharmacodynamics and pharmacokinetics, suboptimal prescribing and adverse effects among this growing cohort of the population. In the fi rst of two articles, we begin by considering these issues and posit four key questions which should be considered when prescribing for older adults. Does this agent refl ect the priorities of the patient? Are there alternatives -with greater effi cacy, effectiveness or tolerability -that might be considered? Are the dose, frequency and formulation appropriate? How does this prescription relate to concurrent medication? We also describe current drug therapies in two disease states with a predilection for older adults: Alzheimer's disease (AD) and osteoporosis. Using these examples we highlight the limitations of evidencebased medicine and guidelines in this cohort of the population, illustrating the reliance on sub-group analysis to demonstrate the effi cacy of drug therapies for older adults in osteoporosis and the underutilisation of appropriate treatments for patients with AD as a result of fl awed guidelines.

show abstract

“…4 Persistence with OAB medication has been found to be lower than for oral antidiabetics, statins, angiotensin receptor blockers, bisphosphonates or prostaglandins. 5 Importantly, most of the discontinuations occur within the first two months of treatment. 5 The most common reasons patients give for discontinuing therapy are that they don't like being on any medications, they don't like taking medications for too long, they learned to get by without medication, the drug didn't work as expected, or side effects were a problem.…”

Section: Antimuscarinic Therapy: Strengths and Weaknessesmentioning

confidence: 99%